文献速递肾癌与肾肿瘤

细胞周期增殖多基因特征可改善肾癌根治术后5年死亡预测

A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2017-12-14

在565例接受根治性肾切除术的局限性透明细胞、乳头状或嫌色细胞肾癌患者中,评估细胞周期增殖(CCP)评分对长期肿瘤学结局的预测价值。CCP评分是复发(HR 1.50,95%CI 1.07-2.09)和疾病特异性死亡(HR 2.49,95%CI 1.53-4.04)的独立预测因子。复合R-CCP评分将患者分为低危(n=338)和高危(n=202)两组,5年癌症特异性生存概率分别为99%和84%(p<0.001)。

要点

  • CCP评分是肾癌根治术后复发和疾病特异性死亡的独立预测因子。
  • 复合R-CCP评分将患者分为低危和高危两组,5年癌症特异性生存概率分别为99%和84%。
  • 将分子分类器与基线临床变量结合可实现准确的患者个体化风险评估。

核心结论

  • CCP评分是接受肾切除术的肾癌患者长期肿瘤学结局的显著独立预测因子。
  • 将分子分类器与基线临床变量结合可实现准确的患者个体化风险评估,用于指导临床管理。

研究设计与样本

  • 在565例接受根治性肾切除术的局限性透明细胞、乳头状或嫌色细胞肾癌患者中测定细胞周期增殖(CCP)评分。
  • 主要终点为疾病特异性死亡(DSM),复发为次要终点,采用Cox比例风险生存分析评估与结局的关联。
  • 将CCP评分与Karakiewicz列线图比较,并开发复合(R-CCP)评分。

主要发现

  • 5年内68例(12%)复发,32例(6%)死于疾病。
  • 使用基线列线图调整临床变量后,CCP评分是复发的独立预测因子(HR 1.50,95%CI 1.07-2.09)。
  • 使用基线列线图调整临床变量后,CCP评分是DSM的独立预测因子(HR 2.49,95%CI 1.53-4.04)。
  • 复合R-CCP评分的Harrell一致性指数为0.87,将患者分为低危(n=338)和高危(n=202)两组,5年癌症特异性生存概率分别为99%和84%(p<0.001)。

临床怎么用

  • 将CCP评分与基线临床变量结合形成的R-CCP评分可用于肾癌根治术后患者的个体化风险评估,以指导临床管理。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a critical need for improved prognostic discrimination in patients with renal cell carcinoma (RCC) given the increasing awareness that some patients may be managed with active surveillance, while others with higher-risk disease might benefit from adjuvant therapy following surgery. OBJECTIVE: To determine whether a multigene proliferation signature predicts long-term oncologic outcomes in surgically resected RCC. DESIGN, SETTING, AND PARTICIPANTS: The cell cycle proliferation (CCP) score was determined after radical nephrectomy for localized clear cell, papillary, or chromophobe RCC in 565 patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary end point was disease-specific mortality (DSM), and disease recurrence was a secondary end point. Association with outcomes was evaluated by Cox proportional hazards survival analysis. The CCP score was compared with the Karakiewicz nomogram, and a composite (R-CCP) score was developed. RESULTS AND LIMITATIONS: A total of 68 patients (12%) recurred and 32 (6%) died of disease within 5 yr of nephrectomy. The CCP score was an independent predictor of recurrence (hazard ratio [HR] 1.50, 95% confidence interval [CI] 1.07-2.09) and DSM (HR 2.49, 95% CI 1.53-4.04) after adjusting for clinical variables using the baseline nomogram. The composite R-CCP score gave a Harrell's concordance index of 0.87 and stratified patients into low- (n=338) and high-risk (n=202) categories with 99% and 84% cancer-specific survival probabilities, respectively (p<0.001). CONCLUSIONS: The CCP score is a significant, independent predictor of long-term oncologic outcomes in patients who have undergone nephrectomy for RCC. Combining the molecular classifier with baseline clinical variables allows for accurate, patient-specific risk assessment for use in guiding clinical management. PATIENT SUMMARY: In this study, we sought to understand how well gene expression information from individual kidney tumors can predict cancer recurrence and death following surgical removal. We found that the combination of the gene expression test and clinical characteristics provides an accurate prognostic assessment to help inform clinical decisions.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Morgan TM, Mehra R, Tiemeny P, et al. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. Eur Urol. 2017. PMID: 29249291. doi:10.1016/j.eururo.2017.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。